Peter Alping

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jag är en Postdoktor vid Avdelningen för Klinisk Epidemiologi, Institutionen för Medicin, Solna. Min forskning är huvudsakligen fokuserad på multipel skleros.

Artiklar

Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 2025;:1-9
Completeness and generalizability of the Swedish MS register
Alping P; Frisell T; He A; Hillert J; Fink K; McKay KA
Article: MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL. 2025;11(1):20552173251314118
Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
Sandesjo F; Alping P; Fink K; Wickstrom R; Piehl F; Frisell T; Mckay KA
Article: ANNALS OF NEUROLOGY. 2024;96(4):678-693
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Piehl F; Alping P; Virtanen S; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Mellergard J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Frisell T
Article: ANNALS OF NEUROLOGY. 2024;96(4):694-703
Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Hu Y; Frisell T; Alping P; Song H; Pawitan Y; Fang F; Piehl F
Article: ANNALS OF NEUROLOGY. 2024;95(6):1099-1111
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study
Alping P; Neovius M; Piehl F; Frisell T
Article: MULTIPLE SCLEROSIS JOURNAL. 2023;29(6):731-740
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Fink K; Gorczyca A; Alping P; Englund S; Farmand S; Langer-Gould AM; Piehl F; McKay K; Frisell T; Razaz N
Article: NEUROLOGY. 2021;96(11):e1574-e1584
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
Alping P; Burman J; Lycke J; Frisell T; Piehl F
Article: ANNALS OF NEUROLOGY. 2020;87(5):688-699
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: JAMA NEUROLOGY. 2020;77(2):184-191
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: EPIDEMIOLOGY. 2019;30(2):230-233
Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations
Alping P; Piehl F; Langer-Gould A; Frisell T; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Kockum I; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Virtanen S; Vrethem M
Article: NEUROLOGY. 2016;87(20):2074-2081
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Salzer J; Svenningsson R; Alping P; Novakova L; Bjorck A; Fink K; Islam-Jakobsson P; Malmestrm C; Axelsson M; Vagberg M; Sundstrom P; Lycke J; Piehl F; Svenningsson A
Article: ANNALS OF NEUROLOGY. 2016;79(6):950-958
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Lycke J; Svenningsson A; Piehl F

Anställningar

Postdoktor, Medicin, Solna, Karolinska Institutet, 2023-2026
AT-Läkare, Karolinska Universitetssjukhuset, 2021-2023
Doktorand, Klinisk neurovetenskap, Karolinska Institutet, 2016-2022
Läkare, Stockholms Läns Sjukvårdsområde (SLSO), 2020-2020

Examina och utbildning

Medicine Doktorsexamen, Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis, Institutionen för klinisk neurovetenskap, Karolinska Institutet, 2022
Läkarexamen, Karolinska Institutet, 2017

Om mig

Artiklar

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI